Quest Diagnostics (DGX) PT Raised to $115 at Canaccord Genuity Following Strong 1Q Report; 'Continues to Prove Skeptics Wrong... Q1 was a Blowout'
Tweet Send to a Friend
Canaccord Genuity raised its price target on Quest Diagnostics (NYSE: DGX) to $115.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
